Key result
Reduced-dose DOACs provide comparable efficacy to full-dose regimens for extended VTE treatment.
Why the study?
Venous thromboembolism often necessitates extended anticoagulation, but the optimal long-term DOAC dosing strategy—reduced versus full dose—remains uncertain.
Do reduced-dose DOACs provide comparable efficacy and safety to full-dose DOACs for extended treatment of VTE?
Systematic Review
Do reduced-dose DOACs provide comparable efficacy and safety to full-dose DOACs for extended treatment of VTE?
Reduced-dose DOACs offer comparable efficacy to full-dose regimens for extended VTE treatment, with a significantly lower risk of bleeding.
Answers are grounded in this paper and cite their sources.
Reduced-dose DOACs were not noninferior for recurrent VTE; challenges dose-reduction assumptions and leaves optimal extended regimens open.
Background Venous thromboembolism (VTE) often necessitates extended anticoagulation to reduce the risk of recurrence. While direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists due to their improved safety and convenience, the optimal long-term dosing strategy (reduced vs full dose) remains uncertain. This systematic review assesses the efficacy and safety outcomes of reduced-dose DOACs compared with full-dose therapy for extended VTE treatment. Methods We conducted a systematic review of randomized controlled trials (RCTs) comparing reduced-dose and full-dose DOACs in patients with VTE. Due to heterogeneity in study designs and outcomes, a narrative synthesis was performed. Results Three RCTs were included. In AMPLIFY-EXT, recurrent VTE or death occurred in 1.7% of patients receiving apixaban (both 2.5 mg and 5 mg) versus 8.8% with placebo. In EINSTEIN CHOICE, recurrent VTE occurred in 1.2% and 1.5% of patients receiving rivaroxaban 10 mg and 20 mg, respectively, compared with 4.4% with aspirin. The safety outcomes were comparable between the two DOAC doses in AMPLIFY-EXT and EINSTEIN CHOICE. RENOVE reported 5-year cumulative incidences of recurrent VTE of 2.2% with reduced-dose and 1.8% with full-dose DOACs (hazard ratio 1.32, 95% confidence interval [CI]: 0.67-2.60; P = .23 for non-inferiority). Major or clinically relevant non-major bleeding events occurred in 9.9% patients in the reduced-dose group and 15.2% patients in the full-dose group (HR 0.61; 95% CI 0.48-0.79). Conclusion Current evidence suggest that reduced-dose DOACs provide efficacy comparable to full-dose regimens without a corresponding increase in bleeding events in the extended treatment of VTE.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2025) conducted a systematic review in Venous thromboembolism (VTE). Reduced-dose direct oral anticoagulants (DOACs) vs. Full-dose DOACs was evaluated on Recurrent VTE (HR 1.32, 95% CI 0.67-2.60, p=.23 for non-inferiority). Reduced-dose DOACs provided comparable efficacy to full-dose regimens for extended VTE treatment, with recurrent VTE rates of.
Synapse has enriched 10 related papers. Consider them for comparative context: